JB Pharma Q3 FY26 PAT up by 22% to Rs. 198 Cr
The company recorded revenue of Rs. 1,065 crore in the third quarter of FY26
The company recorded revenue of Rs. 1,065 crore in the third quarter of FY26
The initiative is being led through the Bank’s CSR programme, Parivartan, in partnership with the Indian Cancer Society
Approval marks Venus Remedies’ first anti-infective marketing authorization in Indonesia and enables the country’s first generic entry for this critical antibiotic combination
The feature will be available across all Max Healthcare facilities, offering patients consistent and convenient access to services nationwide
Backed by two CAP - accredited genomics labs in Delhi NCR and Mumbai, supporting oncology, reproductive health, neurology, transplant immunology, and rare diseases
New 35,000-square-foot facility in Winter Park will expand RLT manufacturing footprint to optimize delivery for patients across southeastern US
Phase 3 study met all primary and secondary endpoints, demonstrating superior convenience, strong efficacy, and excellent safety versus conventional ondansetron injections
This product has only one approved generic and one authorized generic with an addressable market share of US$ 172 million
Subscribe To Our Newsletter & Stay Updated